Prognostic role of C-reactive protein in gastric cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 10, 2013, Pages 5735-5740

  Yu, Qing ^a   Yu, Xiong Fei ^a   Zhang, Shou De ^b   Wang, Hao Hao ^a   Wang, Hai Yong ^a   Teng, Li Song ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

C reactive protein; Gastric carcinoma; Meta analysis; Prognosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; CANCER STAGING; FEMALE; HUMAN; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84890478318     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.10.5735     Document Type: Article

References (49)

1. Aizawa M, Gotohda N, Takahashi S, Konishi M, Kinoshita T (2011). Predictive value of baseline neutrophil/lymphocyte ratio for t4 disease in wall-penetrating gastric cancer. World J Surg, 35, 2717-22.
2. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to virchow? Lancet, 357, 539-45.
3. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
4. Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78.
5. Bonner JA, Harari PM, Giralt J, et al (2010). Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 11, 21-8.
6. Caruso R, Pallone F, Monteleone G (2007). Emerging role of il-23/il-17 axis in h pylori-associated pathology. World J Gastroenterol, 13, 5547-51.
7. Catalano V, Labianca R, Beretta GD, et al (2009). Gastric cancer. Crit Rev Oncol Hematol, 71, 127-64.
8. Chang CC, Sun CF, Pai HJ, et al (2010). Preoperative serum c-reactive protein and gastric cancer; Clinical-pathological correlation and prognostic significance. Chang Gung Med J, 33, 301-12.
9. Chen W, Zheng R, Zhang S, et al (2013). Report of incidence and mortality in china cancer registries, 2009. Chin J Cancer Res, 25, 10-21.
10. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 52, 6735-40.
11. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7.
12. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006). Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer, 94, 637-41.
13. Crumley AB, Stuart RC, McKernan M, McMillan DC (2010). Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg, 34, 2393-8.
14. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20.
15. Egger M, Davey SG, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.
16. Forman D (2001). Gastric cancer and helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut, B, 347-53.
17. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003). Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable nonsmall- cell lung cancer. Br J Cancer, 89, 1028-30.
18. Fujitani K, Yamada M, Hirao M, Kurokawa Y, Tsujinaka T (2011). Optimal indications of surgical palliation for incurable advanced gastric cancer presenting with malignant gastrointestinal obstruction. Gastric Cancer, 14, 353-9.
19. Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med, 340, 448-54.
20. Gencer D, Kastle-Larralde N, Pilz LR, et al (2009). Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie, 32, 380-6.
21. Hashimoto K, Takashima A, Nagashima K, et al (2010). Progressionfree survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol, 136, 1059-64.
22. Heikkila K, Ebrahim S, Lawlor DA (2007). A systematic review of the association between circulating concentrations of c reactive protein and cancer. J Epidemiol Community Health, 61, 824-33.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
24. Hurlimann J, Thorbecke GJ, Hochwald GM (1966). The liver as the site of c-reactive protein formation. J Exp Med, 123, 365-78.
25. Hwang JE, Kim HN, Kim DE, et al (2011). Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer, 11, 489.
26. Iwasa S, Nakajima TE, Nakamura K, et al (2011). Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study. Int J Clin Oncol, 16, 57-62.
27. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
28. Jeong JH, Lim SM, Yun JY, et al (2012). Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology, 83, 292-9.
29. Kao SC, Pavlakis N, Harvie R, et al (2010). High blood neutrophil-tolymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res, 16, 5805-13.
30. Karakiewicz PI, Hutterer GC, Trinh QD, et al (2007). C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a european study of 313 patients. Cancer, 110, 1241-7.
31. Kwon HC, Kim SH, Oh SY, et al (2012). Clinicopathologic significance of expression of nuclear factor-kappab rela and its target gene products in gastric cancer patients. World J Gastroenterol, 18, 4744-50.
32. Macdonald JS, Smalley SR, Benedetti J, et al (2001). Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345, 725-30.
33. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancer-related inflammation. Nature, 454, 436-44.
34. Mohri Y, Tanaka K, Ohi M, et al (2010). Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg, 34, 285-90.
35. Nozoe T, Iguchi T, Adachi E, Matsukuma A, Ezaki T (2011). Preoperative elevation of serum c-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today, 41, 510-3.
36. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
37. Parsonnet J, Friedman GD, Vandersteen DP, et al (1991). Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med, 325, 1127-31.
38. Pine JK, Fusai KG, Young R, et al (2009). Serum c-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol, 35, 605-10.
39. Proctor MJ, Morrison DS, Talwar D, et al (2011). An inflammationbased prognostic score (mgps) predicts cancer survival independent of tumour site: a glasgow inflammation outcome study. Br J Cancer, 104, 726-34.
40. Sakuramoto S, Sasako M, Yamaguchi T, et al (2007). Adjuvant chemotherapy for gastric cancer with s-1, an oral fluoropyrimidine. N Engl J Med, 357, 1810-20.
41. Shimura T, Kitagawa M, Yamada T, et al (2012). C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res, 32, 491-6.
42. Talmadge J E, Fidler I J (2010). Aacr centennial series: the biology of cancer metastasis: historical perspective. Cancer Res, 70, 5649-69.
43. Tillett W S, Francis T (1930). Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med, 52, 561-71.
44. Ulich TR, Del CJ, Guo K, Souza L (1989). The hematologic effects of chronic administration of the monokines tumor necrosis factor, interleukin-1, and granulocyte-colony stimulating factor on bone marrow and circulation. Am J Pathol, 134, 149-59.
45. Ulich TR, Del CJ, Keys M, Granger GA, Ni RX (1987). Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol, 139, 3406-15.
46. Wang DS, Ren C, Qiu MZ, et al (2012). Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage iii gastric cancer. Tumour Biol, 33, 749-56.
47. Wells GA, Shea B, O'Connell D, et al (2008). The newcastleottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm, Accessed 1 January 2008
48. Woo Y, Hyung WJ, Obama K, et al (2012). Elevated high-sensitivity c-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol, 105, 405-9.
49. Zheng ZX, Zheng RS, Chen WQ (2013). An analysis of incidence and mortality of stomach cancer in china, 2009. China Cancer, 327-32.